# Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas

> **NCT05956041** · PHASE2 · RECRUITING · sponsor: **University of Michigan Rogel Cancer Center** · enrollment: 23 (estimated)

## Conditions studied

- Cutaneous T Cell Lymphoma
- Fungoides Mycosis Sezary Syndrome

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Mogamulizumab

## Key facts

- **NCT ID:** NCT05956041
- **Lead sponsor:** University of Michigan Rogel Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-12-06
- **Primary completion:** 2026-12
- **Final completion:** 2027-12
- **Target enrollment:** 23 (ESTIMATED)
- **Last updated:** 2026-05-05

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05956041

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05956041, "Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05956041. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*